282 related articles for article (PubMed ID: 37490255)
41. A microRNA meta-signature for pancreatic ductal adenocarcinoma.
Frampton AE; Giovannetti E; Jamieson NB; Krell J; Gall TM; Stebbing J; Jiao LR; Castellano L
Expert Rev Mol Diagn; 2014 Apr; 14(3):267-71. PubMed ID: 24575833
[TBL] [Abstract][Full Text] [Related]
42. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
43. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
44. Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool?
Tarasiuk A; Mackiewicz T; Małecka-Panas E; Fichna J
Cancer Biol Ther; 2021 Jun; 22(5-6):347-356. PubMed ID: 34224317
[TBL] [Abstract][Full Text] [Related]
45. Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC.
Kim MW; Koh H; Kim JY; Lee S; Lee H; Kim Y; Hwang HK; Kim SI
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948417
[TBL] [Abstract][Full Text] [Related]
46. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Zhu L; Wang X
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32024063
[TBL] [Abstract][Full Text] [Related]
47. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.
Rajamani D; Bhasin MK
Genome Med; 2016 May; 8(1):38. PubMed ID: 27137215
[TBL] [Abstract][Full Text] [Related]
48. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
49. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma.
Bai Z; Sun J; Wang X; Wang H; Pei H; Zhang Z
Oncol Rep; 2015 Aug; 34(2):595-602. PubMed ID: 26062664
[TBL] [Abstract][Full Text] [Related]
51. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
[TBL] [Abstract][Full Text] [Related]
52. Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature.
Wnuk J; Strzelczyk JK; Gisterek I
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982210
[TBL] [Abstract][Full Text] [Related]
53. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance.
Meng Q; Liang C; Hua J; Zhang B; Liu J; Zhang Y; Wei M; Yu X; Xu J; Shi S
Theranostics; 2020; 10(9):3967-3979. PubMed ID: 32226532
[No Abstract] [Full Text] [Related]
54. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
[TBL] [Abstract][Full Text] [Related]
56. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma.
Preis M; Gardner TB; Gordon SR; Pipas JM; Mackenzie TA; Klein EE; Longnecker DS; Gutmann EJ; Sempere LF; Korc M
Clin Cancer Res; 2011 Sep; 17(17):5812-21. PubMed ID: 21652542
[TBL] [Abstract][Full Text] [Related]
58. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
[TBL] [Abstract][Full Text] [Related]
59. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
[TBL] [Abstract][Full Text] [Related]
60. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]